highly pathogenic avian influenza

(redirected from H5N1)
Also found in: Acronyms, Wikipedia.

highly pathogenic avian influenza

Abbreviation: HPAI
Any genetic variant of avian influenza A that causes serious illness, or carries a high probability of death, in infected birds.
See also: influenza
References in periodicals archive ?
Most human cases of H5N1 infection in Egypt were caused by infection with subclade 2.
H5N1 bird flu, which first infected humans in 1997 in Hong Kong, has since spread from Asia to Europe and Africa and has become entrenched in poultry in some countries, causing millions of poultry infections and several hundred human deaths.
H5N1 is a highly pathogenic influenza virus which first emerged in Asia but spread around the world.
tracking of wild waterbirds in Qinghai-Tibetan Plateau has shown that wild birds play a role in the spread of H5N1 (Prosser et al.
The latest deaths from H5N1, a strain that has killed more than 400 people worldwide since first appearing in 2003, were reported in the North African country in the past two weeks.
The company also unveiled it would present two synthetic vaccine candidates against H7N9 and H5N1 strains at the World Vaccine Congress Europe, to be held on October 16-17 in Lille, France.
The FAO's chief veterinary officer, Juan Lubroth, said the H5N1 virus was most entrenched in Egypt, Indonesia, China, Bangladesh, India, and Vietnam.
of laboratory tests has shown the dead house crow found in Sham Shui Po to be H5N1 positive.
None of the cats showed evidence of infection with H5N1 virus.
The researchers who have published their work in the international medical journal The Lancet identified the H5N1 isolated in both men as genetically identical except for one small change in the nucleic acid chain making up the virus' genetic structure.
Authorities yesterday confirmed India's worst outbreak of bird flu was the virulent H5N1 virus strain and announced plans to slaughter two million birds in a bid to contain the disease.
CHICAGO -- The MF59-adjuvanted H5N1 influenza vaccine was as well tolerated as the widely used adjuvanted seasonal FLUAD influenza vaccine among adults in a large phase III multicenter study sponsored by Novartis Vaccines.